Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,450 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Primary Parkinsonism Clear all
Completed No phase listed Observational

Implantable Systems Performance Registry

NCT00959296
View directory record Official record
Conditions
Spinal Cord Stimulation, Deep Brain Stimulation, Drug Infusion (Implantable Pumps), Sacral Neuromodulation
Interventions
Various
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
Not listed
Enrollment
10,981 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
43
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Aliso Viejo, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 31, 2026, 1:22 AM EDT
Terminated Phase 4 Interventional Results available

Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment

NCT02365870
View directory record Official record
Conditions
Anxiety Disorders, Parkinson Disease
Interventions
rotigotine transdermal patch, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 89 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 31, 2026, 1:22 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

NCT03781167
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 31, 2026, 1:22 AM EDT
Completed Not applicable Interventional

A Novel Balance Program to Improve Balance in People With Parkinson's Disease

NCT05906875
View directory record Official record
Conditions
Rehabilitation Exercise, Physical Therapy
Interventions
Lateral Stepping Exercise 1, Lateral Stepping Exercise 2, Lateral Stepping Exercise 3, Lateral Stepping Exercise 4, Lateral Stepping Exercise 5
Other
Lead sponsor
New York Institute of Technology
Other
Eligibility
50 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 31, 2026, 1:22 AM EDT
Completed Phase 3 Interventional

Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations

NCT00203034
View directory record Official record
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate, 1.0 mg rasagiline mesylate, Placebo
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Oct 31, 2026, 1:22 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)

NCT03305809
View directory record Official record
Conditions
Lewy Body Dementia
Interventions
LY3154207, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years to 85 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 31, 2026, 1:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Neural Correlates of Cognition in Parkinson's Disease

NCT02975193
View directory record Official record
Conditions
Parkinson Disease
Interventions
Computer task assessing cognition, Impulsive-Compulsive Disorders in Parkinson's Disease, Deep Brain Stimulation Surgery
Behavioral · Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 31, 2026, 1:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Molecular Epidemiology of Parkinson's Disease

NCT00042107
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
Not listed
Enrollment
2,022 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2005
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Oct 31, 2026, 1:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Occupancy of Adenosine A2A Receptors Using the PET Radiotracer [18F]MNI-444

NCT05009199
View directory record Official record
Conditions
Healthy Volunteer
Interventions
[18F]MNI-444
Drug
Lead sponsor
Invicro
Other
Eligibility
30 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 31, 2026, 1:22 AM EDT
Completed Phase 2 Interventional Results available

Intranasal Insulin in Parkinson's Disease

NCT04251585
View directory record Official record
Conditions
Parkinson Disease
Interventions
Regular Novolin R, Placebo
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
41 Years to 89 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 31, 2026, 1:22 AM EDT
Completed Not applicable Interventional Results available

Dual-task Augmented Reality for PD DBS

NCT06418152
View directory record Official record
Conditions
Parkinson's Disease, Deep Brain Stimulation
Interventions
Multi-modal treatment
Behavioral
Lead sponsor
Jay Alberts
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 31, 2026, 1:22 AM EDT
Completed Phase 3 Interventional Results available

Study of Urate Elevation in Parkinson's Disease, Phase 3

NCT02642393
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Inosine, Placebo
Drug
Lead sponsor
Michael Alan Schwarzschild
Other
Eligibility
30 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 31, 2026, 1:22 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies

NCT07640555
View directory record Official record
Conditions
Multiple System Atrophy (MSA), Healthy Adult, Parkinson Disease
Interventions
[¹⁸F]MODAG-009 PET imaging
Drug
Lead sponsor
MODAG GmbH
Industry
Eligibility
50 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 31, 2026, 1:22 AM EDT
Completed Phase 1 Interventional Results available

Barre Exercise in Parkinson's

NCT06203990
View directory record Official record
Conditions
Parkinson Disease
Interventions
Barre exercise
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 31, 2026, 1:22 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease

NCT02469090
View directory record Official record
Conditions
Parkinson Disease, Off Episodes
Interventions
APL-130277, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 31, 2026, 1:22 AM EDT
Active, not recruiting Not applicable Interventional

Remote Therapeutic Monitoring Exercise Tracking

NCT06306768
View directory record Official record
Conditions
Parkinson Disease, Multiple Sclerosis
Interventions
Activity Monitoring
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 31, 2026, 1:22 AM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

NCT04095793
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Interventions
ampreloxetine
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
30 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
13
States / cities
Colorado Springs, Colorado • Boca Raton, Florida • Port Charlotte, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 31, 2026, 1:22 AM EDT
Recruiting Not applicable Interventional

Evaluation of Neurocognitive Changes in Parkinson's Disease After Low Frequency Burst Stimulation

NCT05307055
View directory record Official record
Conditions
Parkinson Disease
Interventions
STN DBS - Theta Burst, STN DBS - Gamma
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 31, 2026, 1:22 AM EDT
Terminated Phase 4 Interventional

Clinical Effects of Vitamin D Repletion in Patients With Parkinson's Disease

NCT00571285
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Vitamin D3, Vitamin D3 - high dose, Placebo
Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 31, 2026, 1:22 AM EDT
Completed No phase listed Observational

Measurement of Gait Using Opal APDM and Gait Mat in Parkinsonism

NCT02064543
View directory record Official record
Conditions
Parkinsonism
Interventions
GAITRite, ADPM
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 31, 2026, 1:22 AM EDT
Terminated Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

NCT05979415
View directory record Official record
Conditions
Parkinson Disease
Interventions
Apomorphine Cartridge
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
30 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
Scottsdale, Arizona • Tucson, Arizona • Fountain Valley, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 31, 2026, 1:22 AM EDT
Completed Phase 1 Interventional

A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease.

NCT05924243
View directory record Official record
Conditions
Parkinson Disease
Interventions
RO7486967, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Englewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 31, 2026, 1:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms

NCT07182058
View directory record Official record
Conditions
PARKINSON DISEASE (Disorder)
Interventions
Transcranial Electrical Stimulation Device
Device
Lead sponsor
U: The Mind Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 31, 2026, 1:22 AM EDT
Completed Phase 4 Interventional

Brain Perfusion & Oxygenation in Parkinson's Disease With NOH

NCT03229174
View directory record Official record
Conditions
Parkinson Disease, Neurogenic Orthostatic Hypotension
Interventions
Droxidopa, Placebo
Drug
Lead sponsor
William Ondo, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Oct 31, 2026, 1:22 AM EDT